Joshua M. Liao & Michael A. Fischer | Huffington Post
In the first year after the approval of sofosbuvir by the FDA, there was a rapid, widespread increase in Medicaid spending on sofosbuvir, but with substantial variation across states. READ MORE
Source: AJPH. 2017.
Source: NEJM 2015; 373:1279-1281.
Joshua M. Liao & Michael A. Fischer | American Journal of Public Health
Facing constrained budgets, most state Medicaid programs adopted prior authorization criteria for sofosbuvir, an expensive but effective treatment for hepatitis C. Despite the potential cost savings associated with strict behavioral criteria, they raise troubling questions in terms of public health as well as medical ethics, clinical evidence, and potentially federal law. READ MORE
Joshua M. Liao & Mark V. Pauly | Health Affairs Blog
Amid scrutiny of high pharmaceutical drug prices, debate about the value of “orphan drugs" has captured public and policy maker attention. Policy makers have expressed concern about the effect of this dynamic on patients and the public. READ MORE
Joshua M. Liao & Mark V. Pauly | Philadelphia Inquirer (Health Cents)
The outcry and scrutiny over drug pricing policies has amplified the national debate over high specialty drug costs. Not all high-priced drugs, however, are created equal. READ MORE
Copyright 2019 © Joshua Liao. All rights reserved